Xencor appoints John Desjarlais as Chief Scientific Officer Xencor announced the appointment of John R. Desjarlais to senior vice president of research and chief scientific officer. Desjarlais joined Xencor in 2001 and was promoted to vice president of research in 2006, where he oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of drug candidates.
MorphoSys and Xencor publish final results from Phase 1/2a trial of MOR208 MorphoSys and Xencor (XNCR) announced the publication of final results of a Phase 1/2a trial evaluating MOR208 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies. MOR208 was in-licensed by MorphoSys from Xencor in 2010.The results demonstrate that the drug was well tolerated and achieved durable responses in a high risk and poor prognosis patient population with significant progression-free survival achieved.